beacon-intelligence.com Open in urlscan Pro
20.50.64.6  Public Scan

Form analysis
3 forms found in the DOM

GET /

<form class="search-form" method="get" action="/">
  <input type="text" name="s" placeholder="Search...">
</form>

GET https://beacon-intelligence.com/

<form role="search" method="get" class="wpr-search-form" action="https://beacon-intelligence.com/">
  <label for="search-form-65a7746c9c71c"></label>
  <input type="search" class="wpr-search-field" placeholder="Search..." value="" name="s" title="Search for:">
  <button type="submit" class="wpr_submit">
    <i class="wpr-icon-search"></i>
  </button>
</form>

GET https://beacon-intelligence.com/

<form role="search" method="get" class="wpr-search-form" action="https://beacon-intelligence.com/">
  <label for="search-form-65a7746ca18c3"></label>
  <input type="search" class="wpr-search-field" placeholder="Search..." value="" name="s" title="Search for:">
  <button type="submit" class="wpr_submit">
    <i class="wpr-icon-search"></i>
  </button>
</form>

Text Content

 * Home
 * Drugs & Trials
   * Beacon ADC
   * Beacon Bispecific
   * Beacon Cancer Vaccine
   * Beacon Cell Therapy
   * Beacon Checkpoint
   * Beacon Cytokine
   * Beacon DDR
   * Beacon Gene Therapy
   * Beacon Immune Tolerance
   * Beacon Microbiome
   * Beacon Oncolytic Viruses
   * Beacon RNA
   * Beacon TPD
 * Biomarkers & Assays
   * Lung Cancer
 * About
   * News
 * Events
 * Resources
 * Contact
 * Login




MAKE FASTER, BETTER DRUG DEVELOPMENT DECISIONS

Therapeutics which exploit the DNA damage response (DDR) and optimize synthetic
lethality have proved to be effective anti-cancer treatments. With four
FDA-approved PARP inhibitors, the field is expanding rapidly both within and
beyond PARP.

Keep track of this evolving landscape, including novel approaches and
combination strategies, using Beacon DDR. In one easy-to-use database, Beacon
DDR allows you to rapidly find the information you need and focus time on
advancing your research.

Request a demoFind out more

Home > Beacon DDR


BEACON DDR

HOW THE MOST COMPLETE CLINICAL TRIAL AND DRUG LANDSCAPE FOR DDR CAN HELP YOU

WHAT WE COVER

Beacon DNA Damage Response (DDR) covers trial and drug records for clinical,
preclinical, approved and discontinued therapeutics targeting key points in DNA
damage response pathways.  

This module identifies drugs utilizing the concept of synthetic lethality, and
covers DDR repair pathway components, including: 

 * Damage Sensors  
 * Signalling/Mediator Proteins  
 * Effector Proteins  
 * Cell Cycle Checkpoints  
 * DNA Metabolism when in relation to repair and recombination  

Several key therapeutic targets in the DDR landscape included in this module
are: 

 * PARP  
 * ATM  
 * ATR  
 * CHK1/2  
 * WEE1  
 * DNA-PK 
 * POLQ
 * WRN
 * PARG

New data expansion: Deals and Companies. Gain unparalleled access to in-depth
company profiles and the latest commercial deals. Monitor your competitors and
opportunities as well as benchmark deals and evaluate potential partners. Learn
more about Deals and Companies data by downloading the factsheet.

HOW BEACON HELPS

Here are some examples of how Beacon DDR can accelerate your research programs:

 * Search for DDR drugs across all stages of development so you can accurately
   benchmark your strategies against other preclinical and clinical drugs, and
   investigate the novel approaches used by competitors.
 * Drastically reduce time spent looking through publications and conference
   abstracts for clinical trial results by relying on our comprehensive
   collection of data which can be searched by disease, combination treatments
   and much more.
 * Stay on top of emerging trends and new players in the field with real-time
   updates and alerts, as well as in-depth monthly reports curated by our expert
   analyst team.

HOW BEACON DDR WORKS

Search the trial and drug landscape by target, repair pathway and mechanism of
action alongside 15 other search criteria including disease, line of therapy,
biomarker, sponsor, plus more, to instantly extract the data points you need to
conduct more complex analyses.

Our unique Milestones filter and visualization highlights past, present, and
future drug development milestones including drug and trial readouts, asset
history, and regulatory announcements. This enhancement provides an accurate,
timely and exhaustive single-drug timeline allowing you to benchmark progress in
the DDR space.

HOW WE TARGET THE DATA FOR DNA DAMAGE REPAIR THERAPEUTICS

We house all publicly available sources of data updated with 24 – 48 hours of
publication proactively.  Our sources cover (but are not limited to):

 * Clinical trials registries
 * Scientific journals and publications
 * Company reports and presentations
 * Press releases
 * Conference reports and abstracts
 * Government and regulatory organizations
 * Newspapers and other media
 * Patents




RELATED CONTENT

BEACON DDR: AACR-NCI-EORTC POST-CONFERENCE REPORT 2023

Find out more

BEACON DDR: ESMO POST-CONFERENCE REPORT 2023

Find out more

DDR AACR NCI EORTC PRE-CONFERENCE PLANNER 2023

Find out more


WHAT OUR CUSTOMERS SAY


BEACON IS A GREAT DATABASE THAT PEOPLE SHOULD PAY ATTENTION TO. IT'S MUCH BETTER
THAN MANY OF THE MORE GENERIC DATABASES THAT TRY TO CAPTURE ALL DATA ABOUT
EVERYTHING

Director
Top Biotech Company


OUR DDR EXPERT

KIERAN PINTO IS THE LEAD RESEARCH ANALYST FOR BEACON DDR

SIGN UP TO HIS WEEKLY NEWSLETTER TO UNCOVER THE LATEST INSIGHTS INTO THE DDR
LANDSCAPE USING DATA FROM BEACON.

Subscribe to newsletter


OTHER BEACON SOLUTIONS

ADC
Bispecific
Cancer Vaccine
Cell Therapy
Checkpoint
Cytokine
Immune Tolerance
Gene Therapy
Microbiome
Oncolytic Viruses
RNA
TPD

 

Covering all Antibody Drug Conjugates (ADCs), Small Molecule Drug Conjugates
(SMDCs), Protein Drug Conjugates (PDCs), Immunotoxins and more

Find out more

 

Covering all Bi- and Multi-Specific Antibodies, Antibody Fragments, Augmented
Antibodies and more

Find out more

 

Beacon Cancer Vaccine provides the solution you need to master the prophylactic
and therapeutic cancer vaccines field.

Find out more

 

Covering all genetically and non-genetically engineered allogeneic and
autologous cell-based therapies across all disease indications

Find out more

 

Covering all Immune Checkpoint Combination Trials and Immune Checkpoint
Modulators in development across 27 different checkpoint targets

Find out more

 

Covering all cytokines and drugs that target a cytokine or its immediate
receptor belonging to the Interleukins, Interferons, Colony-stimulating factors,
Transforming growth factor β, Tumour necrosis factor and Chemokines families.

Find out more

 

Covering all therapeutics aimed at treating immune-mediated diseases – Beacon
Immune Tolerance provides drug developers with detailed views of the expanding
immune tolerance landscape.

Find out more

 

From gene-editing technologies, novel delivery systems, and a variety of genetic
materials being used- Beacon Gene Therapy steps into the field to give drug
developers a precise and detailed view of how the gene therapy landscape looks.

Find out more

 

Covering all pharmaceutical grade microbiome-based therapeutics across all
disease indications – Beacon Microbiome provides drug developers with detailed
views of the expanding microbiome landscape.

Find out more

 

From capturing viral family and strains to understanding any genetic
modifications – Beacon Oncolytic Viruses steps into the field to give drug
developers the precise detailed view and broader picture of what is truly
happening in the Oncolytic Virus field.

Find out more

 

Covering Oligonucleotide-based, mRNA-Based, Ribozyme, and gRNA-Mediated Gene
Editing therapies, as well as RNA-Targeted Small Molecules – Beacon RNA covers
all disease indications and many modalities to provide a detailed landscape of
the RNA space.

Find out more

 

Beacon TPD provides the solution you need to master the targeted protein
degradation field.

Find out more


ANY QUESTIONS? CONTACT US

TO LEARN MORE ABOUT HOW WE CAN TAILOR BEACON DDR TO HELP YOU, GET IN TOUCH WITH
OUR SALES TEAM

FRANK PLOWDEN AND JORDAN RUMBELOW

DDR Account Managers

Contact the Team

ABOUT BEACON

We are a clinical trial and pipeline database solution, designed in partnership
with pharmaceutical professionals. We track targeted therapies to provide
accurate, in-depth and real-time information in the rapidly evolving landscape
of drug development.

USEFUL LINKS

 * About
 * Solutions
 * Contact
 * Events
 * Resource Center
 * FAQS
 * Careers

SOLUTIONS

 * Beacon Cell Therapy
 * Beacon Immune Tolerance
 * Beacon RNA
 * Beacon Cancer Vaccine
 * Beacon DDR
 * Beacon Gene Therapy
 * Beacon Bispecific

 * Biomarkers & Assays – Lung Cancer
 * Beacon Microbiome
 * Beacon Cytokine
 * Beacon TPD
 * Beacon Oncolytic Viruses
 * Beacon Checkpoint
 * Beacon ADC

LATEST CONTENT

 * Beacon Cell Therapy: ASH 2023 Conference Coverage
 * Liquid Biopsy Assays For ctDNA Detection Infographic
 * 2nd Molecular Glue Drug Development Summit
 * Beacon DDR: AACR-NCI-EORTC Post-Conference Report 2023
 * 7th CAR-TCR Europe Summit 2024

 * Terms & Conditions
 * Site Map

© 2024 TOAST DESIGN | Reg Office: 52 Grosvenor Gardens, London, SW1W 0AU. Beacon
is a trading name of Hanson Wade
Follow us on social media

 * 
 * Home
 * Drugs & Trials
   * Beacon ADC
   * Beacon Bispecific
   * Beacon Cancer Vaccine
   * Beacon Cell Therapy
   * Beacon Checkpoint
   * Beacon Cytokine
   * Beacon DDR
   * Beacon Gene Therapy
   * Beacon Immune Tolerance
   * Beacon Microbiome
   * Beacon Oncolytic Viruses
   * Beacon RNA
   * Beacon TPD
 * Biomarkers & Assays
   * Lung Cancer
 * About
   * News
 * Events
 * Resources
 * Contact
 * Login
 * 
 * 




This is the brochure-popup

This is the contact us popup